Vaginal CO2 Laser and the Genitourinary Syndrome of Menopause

The Clinical, Histopathological, Cytological and Microbiological Efficacy of the Micro-ablative Fractional CO2 Laser : A Double-blind Randomized Placebo-controlled Trial

This study evaluates the clinical, histopathological, cytological and microbiological efficacy of Microablative Fractional CO2 laser intravaginally administered in postmenopausal women with Genitourinary Syndrome of Menopause. Half participants will receive active CO2 laser therapy, while the other half will receive placebo CO2 laser therapy.

Inclusion Criteria:

• Symptoms of vaginal atrophy (dyspareunia and/or vaginal dryness)
• Menopause

Exclusion Criteria:

• Systemic or local hormonal therapy the last 6 months
• Use of moisturizers or lubricants the last month
• Active genital infection (i.e herpes, vaginitis)
• Prolapse stage >=2
• Underlying pathologies that could interfere with the protocol compliance